Aflibercept biosimilars – so near, yet so far
Ashish Sharma, Se Joon Woo, B. D. Kuppermann
Abstract
1. The development of aflibercept biosimilars faces significant proprietary hurdles. Aflibercept’s complex molecular structure, combined with Regeneron’s robust patent portfolio, creates a challeng...
Topics & Concepts
BiosimilarAfliberceptMedicineIntensive care medicinePharmacologyInternal medicineBevacizumabChemotherapyBiosimilars and Bioanalytical MethodsNeutropenia and Cancer InfectionsPharmaceutical studies and practices